Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Novel targets and treatments for Rhabdomyosarcoma
EF 2019-20
Résumé
"Rhabdomyosarcoma (RMS) is the most common muscle tumor that affects children and young adults. Current treatment involves surgery, chemotherapy, and radiation. Yet despite combination therapy survival rates have not changed in two decades. Although current drug therapy may work initially, often over time the tumors stop responding. To treat the cancer, more toxic drugs are used that can have devastating side effects. Thus, new treatments are needed to optimally combine therapies to improve outcome and limit long-term side effects. Temperature sensitive (TS) forms of drugs have been studied in other types of cancer, such as breast and liver. This includes a drug that works in RMS called doxorubicin, which has the unfortunate side effect of heart failure. In order to release this drug it, and its surrounding tissue including the tumor, must be heated to heated to 42 degrees Celsius. One way to do this is using magnetic resonance guided high intensity focused ultrasound (MRgHIFU) which combines real time imaging and a non-invasive form of heating. We will create RMS tumors in mice and then treat them using the MRgHIFU and TS doxorubicin. We hypothesize that this combination could decrease the tumor growth and minimize the drug's accumulation in the rest of the body by focusing its release at the tumor using the targeted heating from MRgHIFU. This preclinical project would form the basis for the use of MRgHIFU and TS doxorubicin treatment into the pediatric oncology clinic, offering a treatment that could prolong life for patients with RMS and significantly reduce side effects. This approach would be safer than current therapy and would be an exciting transition of MRgHIFU and TS doxorubicin from adult to pediatric therapy expanding treatment options for this challenging disease."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
429085
Name
Wunker Claire
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel targets and treatments for Rhabdomyosarcoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Doxorubicin; Drug Treatment; High Intensity Focused Ultrasound; Hyperthermia; Image Guided Therapy; Rhabdomyosarcoma; Therapy; Toxicity
Abstract
"Rhabdomyosarcoma (RMS) is the most common muscle tumor that affects children and young adults. Current treatment involves surgery, chemotherapy, and radiation. Yet despite combination therapy survival rates have not changed in two decades. Although current drug therapy may work initially, often over time the tumors stop responding. To treat the cancer, more toxic drugs are used that can have devastating side effects. Thus, new treatments are needed to optimally combine therapies to improve outcome and limit long-term side effects. Temperature sensitive (TS) forms of drugs have been studied in other types of cancer, such as breast and liver. This includes a drug that works in RMS called doxorubicin, which has the unfortunate side effect of heart failure. In order to release this drug it, and its surrounding tissue including the tumor, must be heated to heated to 42 degrees Celsius. One way to do this is using magnetic resonance guided high intensity focused ultrasound (MRgHIFU) which combines real time imaging and a non-invasive form of heating. We will create RMS tumors in mice and then treat them using the MRgHIFU and TS doxorubicin. We hypothesize that this combination could decrease the tumor growth and minimize the drug's accumulation in the rest of the body by focusing its release at the tumor using the targeted heating from MRgHIFU. This preclinical project would form the basis for the use of MRgHIFU and TS doxorubicin treatment into the pediatric oncology clinic, offering a treatment that could prolong life for patients with RMS and significantly reduce side effects. This approach would be safer than current therapy and would be an exciting transition of MRgHIFU and TS doxorubicin from adult to pediatric therapy expanding treatment options for this challenging disease."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wunker, Claire
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~